银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02591 银诺医药-B

已收盘 11-02 16:08:15

3.275

-0.125

-3.68%

最高3.740	最低3.225	成交量1,873万
今开3.600	昨收3.400	日振幅15.15%
总市值14.97亿	流通市值13.76亿	总股本4.57亿
成交额6,395万	换手率4.46%	流通股本4.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"银诺医药-B","latestPrice":3.275,"timestamp":1793606895007,"preClose":3.4,"halted":0,"volume":18734000,"delay":0,"changeRate":-0.03676470588235294,"floatShares":420285370,"shares":457000000,"eps":-0.79,"marketStatus":"已收盘","change":-0.125,"latestTime":"11-02 16:08:15","open":3.6,"high":3.74,"low":3.225,"amount":63950068,"amplitude":0.151471,"askPrice":3.28,"askSize":20000,"bidPrice":3.275,"bidSize":1600,"shortable":3,"etf":0,"ttmEps":-0.853301,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793669400000},"marketStatusCode":5,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":3.4,"openAndCloseTimeList":[[1793583000000,1793592000000],[1793595600000,1793606400000]],"volumeRatio":1.448753,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02591","defaultTab":"news","newsList":[{"id":"2679025614","title":"网红减重药竞争集中 单靶点长效药的机会在哪里？对话银诺医药董事长王庆华","url":"https://stock-news.laohu8.com/highlight/detail?id=2679025614","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679025614?lang=zh_cn&edition=full","pubTime":"2026-10-30 08:37","pubTimestamp":1793320647,"startTime":"0","endTime":"0","summary":"【网红减重药竞争集中 单靶点长效药的机会在哪里？对话银诺医药董事长王庆华】2026年上半年，全球主要GLP-1药物销售额合计达到477亿美元，同比增长43%，全年预计突破千亿美元。替尔泊肽半年卖了276.93亿美元，同比增长88%；司美格鲁肽半年卖了175亿美元，增速只有6%。两款产品合计占全球市场绝大部分份额，这一格局年内没有松动迹象。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293915017229.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293915017229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678317100","title":"银诺医药王庆华：创新最终要落脚于综合临床价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2678317100","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678317100?lang=zh_cn&edition=full","pubTime":"2026-10-28 02:38","pubTimestamp":1793126280,"startTime":"0","endTime":"0","summary":"随着肥胖临床研究不断深入，临床端和患者对用药安全、身体组分改善愈发看重，代谢新药的竞争逻辑随之转变：不能只比拼减重数字，更要拿出循证数据，实现减脂护肌、改善内脏脂肪等综合代谢获益。“不少项目只紧盯减重数字，却忽视肌肉流失、肝脂超标等长期隐患。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610283910639721.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610283910639721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676502743","title":"银诺医药-B(02591.HK)：金柏获委任为公司副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2676502743","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676502743?lang=zh_cn&edition=full","pubTime":"2026-10-19 18:13","pubTimestamp":1792404787,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117130640","title":"银诺医药-B（02591）任命金柏为副总裁 负责全球商业化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1117130640","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117130640?lang=zh_cn&edition=full","pubTime":"2026-10-19 18:12","pubTimestamp":1792404744,"startTime":"0","endTime":"0","summary":"2026年10月19日，广州银诺医药集团股份有限公司发布自愿性公告称，董事会已委任金柏先生为公司副总裁，自2026年10月19日起生效，负责集团整体产品商业化及相关事务。银诺医药-B董事会表示，金柏先生在医药产品销售、商业化运营、团队建设及体系化管理方面的经验将有助于公司在全球范围内的商业化布局和发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676350760","title":"银诺医药-B：委任金柏为副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2676350760","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676350760?lang=zh_cn&edition=full","pubTime":"2026-10-19 18:10","pubTimestamp":1792404600,"startTime":"0","endTime":"0","summary":"南财智讯10月19日电，银诺医药-B（02591.HK）发布自愿公告，金柏先生已获委任为公司副总裁，主要负责集团整体产品商业化及相关其他事务，自2026年10月19日起生效。金柏先生在医药产品销售及商业化管理领域拥有超过20年的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610193900006720.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610193900006720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676501933","title":"年内股价暴跌88%后，银诺医药再迎人事震荡：商业化“操盘手”徐文洁辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2676501933","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676501933?lang=zh_cn&edition=full","pubTime":"2026-10-19 17:05","pubTimestamp":1792400745,"startTime":"0","endTime":"0","summary":"2022年4月，徐文洁加入银诺医药出任高级副总裁，同年11月获委任为董事，2024年10月调任执行董事，负责公司整体产品商业化及业务拓展。银诺医药在招股书中提到，徐文洁正在领导公司的依苏帕格鲁肽α的商业化工作。而截至2026年10月16日收盘，公司股价报3.65港元，总市值约16.65亿港元，年初至今跌幅约88%。银诺医药方面，在同日生效的另一项安排中，执行董事黄冰获委任为战略委员会委员，填补徐文洁留下的空缺。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792400248879138100","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186057224","title":"银诺医药-B宣布两名董事辞任并调整战略委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1186057224","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186057224?lang=zh_cn&edition=full","pubTime":"2026-10-16 21:00","pubTimestamp":1792155642,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司10月16日晚间公告称，公司董事会收到两名董事的辞任报告，并同步完成战略委员会成员调整。同日起，执行董事黄冰获委任为战略委员会委员。公告显示，截至公告日，公司董事会由三名执行董事WANG QINGHUA、姜帆及黄冰，两名非执行董事HO KYUNG SHIK，以及三名独立非执行董事陶武平、宋瑞霖、陈向荣组成。公司董事会对徐文洁和衡磊在任期间的贡献表示感谢，并欢迎黄冰履新。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675924625","title":"银诺医药-B(02591.HK)：徐文洁辞任执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2675924625","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675924625?lang=zh_cn&edition=full","pubTime":"2026-10-16 20:58","pubTimestamp":1792155498,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181632949","title":"银诺医药-B：9月股本保持稳定，未有新增发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1181632949","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181632949?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:37","pubTimestamp":1791189452,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司于2026年10月5日发布2026年9月证券变动月报表。报告期为2026年9月1日至9月30日。报告显示，截至2026年9月30日，银诺医药-B注册股本总数为人民币456,819,349元，维持不变。报告期内，上述股份数量均无增减变化。公司在本月并未发生任何新增发行、回购、注销或库藏股等变动。本次公告由公司联席公司秘书杨东妍签署。银诺医药-B重申将继续严格遵守香港联交所《上市规则》及相关法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105926314","title":"银诺医药-B2026年中期营收7,821.80万元 同比增长38.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105926314","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105926314?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:13","pubTimestamp":1790601202,"startTime":"0","endTime":"0","summary":"根据银诺医药-B披露的2026年中期报告，期内实现营收7,821.80万元，同比增长38.56%。报告期内，毛利率为72.50%，相较上年同期89.40%有所下降。从费用结构来看，研发投入为8,529.20万元，相比上年同期的9,908.20万元减少13.90%。销售及分销开支达到6,255.00万元，同比增加42.05%；行政开支为2,670.60万元，同比下降15.36%。经营活动所用现金流量净流出13,536.00万元，上年同期为8,685.20万元，经营性净现金流出同比增加约55.88%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"银诺医药-B2026年中期营收7,821.80万元 同比增长38.56%","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2667666320","title":"黄冰增持银诺医药-B(02591.HK)2400股 每股作价3.89港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666320","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667666320?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:44","pubTimestamp":1789386264,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127325384","title":"银诺医药-B：Cowin Capital Investment III Limited减持，好仓比例降至2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127325384","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127325384?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:23","pubTimestamp":1789118631,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment III Limited于2026年9月10日以每股均价3.8185港元卖出银诺医药-B股份399.00万股，涉资约1523.58万港元。Cowin Capital Investment III Limited此次减持前持有银诺医药-B好仓1441.64万股，占比3.43%；减持后持股量为1042.64万股，好仓比例降至2.48%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196120627","title":"银诺医药-B：Cowin China Growth Fund II, L.P.减持，好仓比例降至2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196120627","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196120627?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:12","pubTimestamp":1789117940,"startTime":"0","endTime":"0","summary":"Cowin China Growth Fund II, L.P.于2026年9月10日以每股均价3.8185港元卖出银诺医药-B股份399.00万股，涉资约1523.58万港元。Cowin China Growth Fund II, L.P.此次减持前持有银诺医药-B好仓1441.64万股，占比3.43%；减持后持股量为1042.64万股，好仓比例降至2.48%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114700606","title":"银诺医药-B：Cowin Capital Investment Limited减持，好仓比例由3.43%降至2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114700606","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114700606?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:46","pubTimestamp":1789033584,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment Limited于2026年9月10日以每股均价3.8185港元卖出银诺医药-B股份399.00万股，涉资约1523.58万港元。Cowin Capital Investment Limited此次减持前持有银诺医药-B好仓1441.64万股，占比3.43%；减持后持股量为1042.64万股，好仓比例降至2.48%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168898987","title":"银诺医药-B：Cowin Capital Investment II LTD减持，好仓比例降至2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168898987","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168898987?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:32","pubTimestamp":1789032777,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment II LTD于2026年9月10日以每股均价3.8185港元卖出银诺医药-B股份399.00万股，涉资约1523.58万港元。Cowin Capital Investment II LTD此次减持前持有银诺医药-B好仓1441.64万股，占比3.43%；减持后持股量为1042.64万股，好仓比例降至2.48%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115796288","title":"银诺医药-B：黄荔减持，好仓比例降至4.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115796288","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115796288?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:22","pubTimestamp":1789032137,"startTime":"0","endTime":"0","summary":"黄荔于2026年9月10日以每股均价3.819港元卖出银诺医药-B（02591）股份519.00万股，涉资约1982.06万港元。黄荔此次减持前持有银诺医药-B好仓2479.11万股，占比5.9%；减持后持股量为1960.11万股，好仓比例降至4.66%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101858139","title":"银诺医药-B：郑伟鹤减持，好仓比例降至4.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101858139","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101858139?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:16","pubTimestamp":1789031770,"startTime":"0","endTime":"0","summary":"于2026年9月10日，郑伟鹤以每股均价3.819港元卖出银诺医药-B股份519.00万股，涉资约1982.06万港元。郑伟鹤此次减持前持有银诺医药-B好仓2479.11万股，占比5.9%；减持后持股量为1960.11万股，好仓比例降至4.66%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180452237","title":"银诺医药-B：郑伟鹤减持，好仓比例降至5.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180452237","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180452237?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:24","pubTimestamp":1788945849,"startTime":"0","endTime":"0","summary":"郑伟鹤于2026年9月8日以每股均价3.6115港元卖出银诺医药-B股份440.00万股，涉资约1589.06万港元。郑伟鹤此次减持前持有银诺医药-B好仓2919.11万股，占比6.95%；减持后持股量为2479.11万股，好仓比例降至5.9%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197227945","title":"银诺医药-B：Cowin Capital Investment III Limited减持，好仓比例降至3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197227945","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197227945?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:33","pubTimestamp":1788860036,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment III Limited于2026年9月8日以每股均价3.6117港元卖出银诺医药-B股份337.00万股，涉资约1217.14万港元。Cowin Capital Investment III Limited此次减持前持有银诺医药-B好仓1778.64万股，占比4.23%；减持后持股量为1441.64万股，好仓比例降至3.43%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129685377","title":"银诺医药-B：Cowin Capital Investment Limited减持，好仓比例降至3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129685377","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129685377?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:33","pubTimestamp":1788860023,"startTime":"0","endTime":"0","summary":"Cowin Capital Investment Limited于2026年9月8日以每股均价3.6117港元卖出银诺医药-B股份337.00万股，涉资约1217.14万港元。Cowin Capital Investment Limited此次减持前持有银诺医药-B好仓1778.64万股，占比4.23%；减持后持股量为1441.64万股，好仓比例降至3.43%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innogenpharm.com","stockEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":-0.1169},{"period":"3month","weight":-0.5317},{"period":"6month","weight":-0.7571},{"period":"1year","weight":-0.8859},{"period":"ytd","weight":-0.889}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0536},{"period":"3month","weight":-0.1001},{"period":"6month","weight":-0.0963},{"period":"1year","weight":-0.1137},{"period":"ytd","weight":-0.0911}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州银诺医药集团股份有限公司是一家主要从事医药产品的研发及商业化的中国投资控股公司。该公司主要从事商业化原研人源长效胰高血糖素样肽-1（GLP-1）受体激动剂。该公司致力于开发糖尿病和其他代谢性疾病的疗法。该公司的主要产品依苏帕格鲁肽α（商品名：怡诺轻）用于治疗2型糖尿病（T2D）。该公司的主要候选药物管线产品包括YN014、YN401、YN209、YN203和YN202。该公司主要在国内市场经营其业务。","exchange":"SEHK","name":"银诺医药-B","nameEN":"INNOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"银诺医药-B,02591,银诺医药-B股票,银诺医药-B股票老虎,银诺医药-B股票老虎国际,银诺医药-B行情,银诺医药-B股票行情,银诺医药-B股价,银诺医药-B股市,银诺医药-B股票价格,银诺医药-B股票交易,银诺医药-B股票购买,银诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}